Get the Stockscreener App
4.35
0.68%
-0.03
Bioage Labs Inc stock is traded at $4.35, with a volume of 546.66K.
It is down -0.68% in the last 24 hours and up +10.41% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$4.38
Open:
$4.54
24h Volume:
546.66K
Relative Volume:
1.90
Market Cap:
$157.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.68%
1M Performance:
+10.41%
6M Performance:
+6.10%
1Y Performance:
+0.00%
1-Day Range:
$4.25
$4.54
1-Week Range:
$4.25
$4.70
52-Week Range:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
1445A SOUTH 50TH STREET, RICHMOND
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.35 | 157.02M | 0 | 0 | 0 | 0.00 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - marketscreener.com
BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks
BioAge Labs Unlocks Massive Aging Database: 17,000 Samples to Power Next-Gen Drug Discovery Platform - Stock Titan
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com
Healthcare companies chase cures and capital in South Florida - Sun Sentinel
An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire
BioAge Labs Elects Directors at Annual Meeting - TipRanks
BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire
Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView
BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com
BioAge Labs Updates Milestones for NLRP3 Program - TipRanks
Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech
BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter
BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks
BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times
Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail
Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview
BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey
Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India
Jefferies maintains hold on BioAge Labs with $4 target - Investing.com
BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com
BioAge advances obesity drug into clinical trials - Investing.com Australia
BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times
BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News
Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan
Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire
Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire
BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsBIOA - ACCESS Newswire
BioAge Labs Advances Pipeline with Strategic Collaborations - TipRanks
BioAge Labs, Inc Q1 Loss Narrows - Nasdaq
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus
Shareholder Rights Advocates at Levi & Korsinsky Investigate BioAge Labs, Inc. (BIOA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
BioAge Labs, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- BIOA - ACCESS Newswire
Investors who lost money on BioAge Labs, Inc. should contact Levi & Korsinsky about an ongoing investigationBIOA - ACCESS Newswire
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):